Deprescribing: A Tool for Cost Reduction and Improved Outcomes?

Everyday there are more news headlines about policymakers addressing different approaches to lowering healthcare and prescription drug costs.

This spring alone saw news about the approval of the second gene therapy Zolgensma (onasemnogene abeparvovec-xioi), a one-time treatment for spinal muscular atrophy (SMA) affecting about 1 in 11,000 babies, with pricing set at $2.1 million, making it the most costly drug on the market.  read more